Management and therapeutic options in pediatric pulmonary hypertension

References

• Wood P. The eisenmenger syndrome or pulmonary hypertension with reversed central shunt. Br. Med. J.2, 701–709 (1958).
   PubMedGoogle Scholar
• Eisenmenger V. Die angeboren defects des kammerscheidewand des herzen. Z. Klin. Med.32, 1–28 (1897).
   Google Scholar
• Heath D, Edwards J. A description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac defects. Circulation18, 533–547 (1958).
   PubMed Web of Science ®Google Scholar
• Rabinovitch M, Keane J, Norwood W. Vascular structure in lung tissue obtained at biopsy correlated with pulmonary haemodynamic findings after repair of congenital heart defects. Circulation69, 655–667 (1984).
   PubMed Web of Science ®Google Scholar
• Rabinovitch M, Pathobiology of pulmonary hypertension: impact on clinical management. Semin. Thorac. Cardiovasc. Surg. Pediatr. Card. Surg. Annu.3, 63–81 (2000).
   Google Scholar
• Andrews R, Tulloh R. Pulmonary hypertension in paediatrics. Cur. Opin. Paediatr.14, 603–605 (2002).
   Google Scholar
• Gibbs J. Recommendations on the management of pulmonary hypertension in clinical practice. Heart86(Suppl. 1), 1–13 (2001).
   PubMedGoogle Scholar
• Proceedings of the 3rd World Symposium on Pulmonary Arterial Hypertension. Venice, Italy, June 23–25. J. Am. Coll. Cardiol.43(12 Suppl. S), S1S–S90 (2003).
   Google Scholar
• Rich S. Primary pulmonary hypertension: executive summary from the world symposium – primary pulmonary hypertension. Available at: http;//www.who.int/ncd/cvd/pph.html, (1998).
   Google Scholar
• Abman SH. Pathogenesis and treatment of neonatal and postnatal pulmonary hypertension. Curr. Opin. Pediatr.6(3), 239–247 (1994).
   Google Scholar
• Humbert M, Nunes H, Sitbon O, Parent F, Herne P, Simonneau G. Risk factors for pulmonary arterial hypertension. Clin. Chest Med.22(3), 459–475 (2001).
   PubMed Web of Science ®Google Scholar
• Luchese S, Manica LJ, Zielinsky P. Intrauterine ductus arteriosus constriction: analysis of a historic cohort of 20 cases. Arq. Bras. Cardiol.81(4), 405–10, 399–404 (2003).
   PubMedGoogle Scholar
• Mark EJ, Patalas ED, Chang HT, Evans RJ, Kessler SC. Fatal pulmonary hypertension associated with short-term use of fenfluramine and phentermine. N. Engl. J. Med.337, 602–606 (1997).
   PubMed Web of Science ®Google Scholar
• Chambers CD, Hernandez-Diaz S, van Marter LJ et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N. Engl. J. Med.354, 579–587 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenzweig EB, Barst JR. Idiopathic pulmonary arterial hypertension in children. Curr. Opin. Pediatr.17(3), 372–380 (2005).
   Web of Science ®Google Scholar
• Haworth SG. Development of the normal and hypertensive pulmonary vasculature. Exp. Physiol.80(5), 843–853 (1995).
   Google Scholar
• Manes A, Campana C. Pulmonary hypertension: classification and diagnostic algorithm. Ital. Heart J.6(10), 834–839 (2005).
   Google Scholar
• Ebeid MR, Ferrer PL, Robinson B, Weatherby N, Gebland H. Doppler echocardiographic evaluation of pulmonary vascular resistance in children with congenital heart disease. J. Am. Soc. Echocardiogr.9(6), 822–831 (1996).
   Google Scholar
• Lopez-Candales A, Dohi K, Rajagopalan N et al. Right ventricular dyssynchrony in patients with pulmonary hypertension is associated with disease severity and functional class. Cardiovasc. Ultrasound3, 23–26 (2005).
   Google Scholar
• Maiya S, Hislop AA, Flynn Y, Haworth SG. Response to bosentan in children with pulmonary hypertension. Heart92(5), 664–670 (2005).
   Google Scholar
• Atz AM, Adatia I, Lock JE, Wessel DL. Combined effects of nitric oxide during acute pulmonary vasodilator testing. J. Am. Coll. Cardiol.33, 813–819 (1999).
   PubMedGoogle Scholar
• Mikhail G, Gibbs J, Richardson M et al. An evaluation of nebulized prostacycin in patients with primary and secondary pulmonary hypertension. Eur. Heart J.18, 1499–1504 (1997).
   Google Scholar
• Holcomb SS. Understanding pulmonary arterial hypertension. Nursing34(9), 50–54 (2004).
   Google Scholar
• Muthurangu V, Taylor A, Andriantsimianova R et al. Ovel method of quantifying pulmonary vascular resistance by use of simultaneous invasive pressure monitoring and phase-contrast magnetic resonance flow. Circulation110(7), 826–834 (2004).
   PubMed Web of Science ®Google Scholar
• Muthurangu V, Atkinson D, Sermesant M et al. Measurement of total pulmonary arterial compliance using invasive pressure monitoring and MR flow quantification during MR-guided cardiac catheterization. Am. J. Physiol. Heart Circ. Physiol.289(3), H1301–H1306 (2005).
   Google Scholar
• Rabinovitch M, Haworth SG, Castaneda AR, Nadas AS, Reid LM. Lung biopsy in congenital heart disease: a morphometric approach to pulmonary vascular disease. Circulation58, 1107–1122 (1978).
   PubMed Web of Science ®Google Scholar
• Meyrick B, Reid L. Ultrastructural findings in lung biopsy material from children with congenital heart defects. Am. J. Pathol.101, 527–537 (1980).
   PubMed Web of Science ®Google Scholar
• Rabinovitch M, Bothwell T, Hayakawa B. Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension: a correlation of light with scanning electron microscopy and transmission electron microscopy. Lab. Invest.55, 632–653 (1986).
   PubMed Web of Science ®Google Scholar
• Taipale J, Lohi J, Saarinen J, Kovanen PT, Keski-Oja J. Human mast cell chymase and leukocyte elastase release latent transforming growth factor B1 from the extracellular matrix of cultured human epithelial and endothelial cells. J. Biol. Chem.270, 4689–4696 (1995).
   PubMed Web of Science ®Google Scholar
• Jones P, Cowan K, Rabinovitch M. Induction of tenascin and fibronectin are features associated with increased smooth muscle cell proliferation during the development of progressive pulmonary hypertension in children. Am. J. Pathol.150, 1349–1360 (1997).
   PubMed Web of Science ®Google Scholar
• Thomson J, Machado RD, Pauciulo MW et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-2, a receptor member of the TGF-β family. J. Med. Genet.37, 741–745 (2000).
   PubMed Web of Science ®Google Scholar
• Derynck R, Zhang EY. SMAD-dependent and Smad-independent pathways in TGF-family signalling. Nature425, 577–584 (2003).
   PubMed Web of Science ®Google Scholar
• Roberts KE, McElroy JJ, Wong WP et al. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur. Respir. J.24(3), 371–374 (2004).
   PubMed Web of Science ®Google Scholar
• Tulloh R, Hislop AA, Boels PJ, Deutsch J, Haworth SG. Chronic hypoxia inhibits postnatal maturation of porcine intrapulmonary artery relaxation. Am. J. Physiol.272, H2436–H2445 (1997).
   Google Scholar
• Black SM, Bekker JM, McMullan DM et al. Alterations in nitric oxide production in 8-week-old lambs with increased pulmonary blood flow. Pediatr. Res.52(2), 233–244 (2002).
   PubMed Web of Science ®Google Scholar
• Adatia I, Haworth S. Circulating endothelin levels in children with congenital heart disease. Br. Heart J.69, 233–236 (1993).
   Google Scholar
• Bando K, Turrentine MW, Sharp TG et al. Pulmonary hypertension after operations for congenital heart disease: analysis of risk factors and management. J. Thorac. Cardiovasc. Surg.112(6), 1600–1607; discussion 1607–1609 (1996).
   PubMed Web of Science ®Google Scholar
• Yuan JX, Rubin JL. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation111(5), 534–538 (2005).
   PubMedGoogle Scholar
• Lindberg L, Olsson AK, Jogi P, Jonmarker C. How common is severe pulmonary hypertension after pediatric cardiac surgery? J. Thorac. Cardiovasc. Surg.123(6), 1155–1163 (2002).
   Google Scholar
• Ohsumi H, Sakamoto M, Yamazaki T, Okumura F. Effects of fentanyl on carotid sinus baroreflex control of circulation in rabbits. Am. J. Physiol.256, R625–R631 (1989).
   Google Scholar
• Levy Tulloh MR, Komai H et al. Maturation of the contractile response and its endothelial modulation in newborn porcine intrapulmonary arteries. Pediatric Res.38, 25–29 (1995).
   PubMed Web of Science ®Google Scholar
• Adatia I, Wessel LD. Therapeutic use of inhaled nitric oxide. Curr. Opin. Pediatr.6(5), 583–590 (1994).
   PubMedGoogle Scholar
• Abman SH. Neonatal pulmonary hxypertension: a physiologic approach to treatment. Pediatr. Pulmonol. Suppl.26, 127–128 (2004).
   Google Scholar
• Adatia I, Perry S, Landzberg M, Moore P, Thompson JE, Wessel DL. Inhaled nitric oxide and hemodynamic evaluation of patients with pulmonary hypertension before transplantation. J. Am. Coll. Cardiol.25(7), 1656–1664 (1995).
   PubMed Web of Science ®Google Scholar
• Wimmer M, Schlemmer M. Long-term hemodynamic effects of nifedipine on congenital heart disease with Eisenmenger's mechanism in children. Cardiovasc. Drugs Ther.6(2), 183–186 (1992).
   PubMed Web of Science ®Google Scholar
• McMahon CJ, Kadkin J, Nihill RM. Rapid regression of primary pulmonary hypertension. Heart86(1), E1 (2001).
   Google Scholar
• Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. Circulation111(24), 3274–3280 (2005).
   PubMed Web of Science ®Google Scholar
• Weimann J, Ullrich R, Hromi J et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology92, 1702–1712 (2000).
   PubMed Web of Science ®Google Scholar
• Matot I, Gozal Y. Pulmonary responses to selective phosphodiesterase-5 and phosphodiesterase-3 inhibitors. Chest 125(2), 644–651 (2004).
   PubMed Web of Science ®Google Scholar
• Atz AM, Lefler AK, Fairbrother DL, Uber WE, Bradley SM. Sildenafil augments the effect of inhaled nitric oxide for postoperative pulmonary hypertensive crises. J. Thorac. Cardiovasc. Surg.124(3), 628–629 (2002).
   PubMed Web of Science ®Google Scholar
• Bharani A, Mathew V, Sahu A, Lunia B. The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension. Indian Heart J.55(1), 55–59 (2003).
   PubMedGoogle Scholar
• Brun H, Holmstrom H, Thaulow E. Sudden death during a change in treatment for pulmonary hypertension. Cardiol. Young15(2), 223–225 (2005).
   Google Scholar
• Della Torre F, Della Torre E, Di Berardino F. Sildenafil in pulmonary hypertension. Sarcoidosis Vasc. Diffuse Lung Dis.22(1), 78–79 (2005).
   Web of Science ®Google Scholar
• Rosenzweig EB, Ivy DD, Widlitz A et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J. Am. Coll. Cardiol.46(4), 697–704 (2005).
   PubMed Web of Science ®Google Scholar
• Barst RJ, Ivy D, Dingemanse J et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension. Clin. Pharmacol. Ther.73(4), 372–382 (2003).
   PubMed Web of Science ®Google Scholar
• Gatzoulis MA, Rogers P, Li W et al. Safety and tolerability of bosentan in adults with Eisenmenger physiology. Int. J. Cardiol.98(1), 147–151 (2005).
   PubMed Web of Science ®Google Scholar
• Apostolopoulou SC, Rammos S. Sitaxsentan in pulmonary arterial hypertension. Chest123(5), 1772; author reply 1772–1723 (2003).
   Google Scholar
• Barst RJ, Langleben D, Frost A et al; STRIDE-1 Study Group. Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med.169(4), 441–447 (2004).
   PubMed Web of Science ®Google Scholar
• Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Clinical efficacy of sitaxsentan, an endothelin – a receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest121(6), 1860–1868 (2002).
   PubMed Web of Science ®Google Scholar
• Prostacyclin: basic principles and clinical application in congestive heart failure and primary pulmonary hypertension. Proceedings of a symposium. Bologna, Italy, November 20, 1993. Am. J. Cardiol.75(3), 1A–73A (1995).
   Google Scholar
• Hermon M, Golej J, Burda G, Marx M, Trittenwein G, Pollak A. Intravenous prostacyclin mitigates inhaled nitric oxide rebound effect: a case control study. Artif. Organs23, 975–978 (1999).
   Web of Science ®Google Scholar
• Barst RJ, Rubin LJ, Long WA et al.; The Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N. Engl. J. Med.334(5), 296–302 (1996).
   PubMed Web of Science ®Google Scholar
• Simonneau G, Barst RJ, Galie N et al; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med.165(6), 800–804 (2002).
   PubMed Web of Science ®Google Scholar
• Vizza CD, Sciomer S, Morelli S et al. Long term treatment of pulmonary arterial hypertension with beraprost, an oral prostacyclin analogue. Heart86(6), 661–5 (2001).
   Google Scholar
• Barst RJ, McGoon M, McLaughlin V et al ; Beraprost Study Group. Beraprost therapy for pulmonary arterial hypertension. J. Am. Coll. Cardiol.41(12), 2119–2125 (2003).
   PubMed Web of Science ®Google Scholar
• Baker SE, Hockman HR. Inhaled iloprost in pulmonary arterial hypertension. Ann. Pharmacother.39(7–8), 1265–1274 (2005).
   PubMedGoogle Scholar
• Clark RH, Huckaby JL, Kueser TJ et al ; Clinical Inhaled Nitric Oxide Research Group. Low-dose nitric oxide therapy for persistent pulmonary hypertension: 1-year follow-up. J. Perinatol.23(4), 300–303 (2003).
   PubMedGoogle Scholar
• Cheever KH. An overview of pulmonary arterial hypertension: risks, pathogenesis, clinical manifestations, and management. J. Cardiovasc. Nurs.20(2), 108–116; quiz 117–118 (2005).
   Google Scholar
• Rosenzweig EB, Barst RJ. Eisenmenger's syndrome: current management. Prog. Cardiovasc. Dis.45, 129–138 (2002).
   Google Scholar
• Andrews R, Tulloh R, Magee A, Anderson D. Atrial septal defect with failure to thrive in infancy: hidden pulmonary vascular disease? Pediatr. Cardiol.23(5), 528–530 (2002).
   PubMed Web of Science ®Google Scholar
• Kumar A, Taylor GP, Sandor GG, Patterson MW. Pulmonary vascular disease in neonates with transposition of the great arteries and intact ventricular septum. Br. Heart J.69(5), 442–445 (1993).
   Google Scholar
• Holcomb R, Tyson RW, Ivy DD, Abman SH, Kinsella JP. Congenital pulmonary venous stenosis presenting as persistent pulmonary hypertension of the newborn. Pedia. Pulmonology28, 301–306 (1999).
   Google Scholar
• Ricci M, Elliott M, Cohen GA et al. Management of pulmonary venous obstruction after correction of TAPVC: risk factors for adverse outcome. Eur. J. Cardiothorac. Surg.24(1), 28–36; discussion 36 (2003).
   Google Scholar
• Rich S, Kaufmann E, Levy SP. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N. Engl. J. Med.327(2), 76–81 (1992).
   PubMed Web of Science ®Google Scholar
• Higenbottam T. Intravenous epoprostenol for primary pulmonary hypertension. N. Engl. J. Med.334(22), 1477; author reply 1477–1478 (1996).
   PubMedGoogle Scholar
• Sandoval J, Aguirre JS, Pulido T et al. Nocturnal oxygen therapy in patients with the Eisenmenger syndrome. Am. J. Respir. Crit. Care Med.164(9), 1682–1687 (2001).
   PubMed Web of Science ®Google Scholar
• Kerstein D, Levy PS, Hsu DT, Hordof AJ, Gersony WM, Barst RJ. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation91(7), 2028–2035 (1995).
   PubMed Web of Science ®Google Scholar
• Micheletti A, Hislop A, Lammers A et al. Role of atrial septostomy in the treatment of children with pulmonary arterial hypertension. Heart (2005) (Epub ahead of print).
   Google Scholar